Amedeo Smart

Free Medical Literature Service

 

Amedeo

Biliary Tract Diseases
  Free Subscription

Articles published in
Hepatology
    March 2026
  1. ZHIXING L, Liu S, Yu H, Yuxi L, et al
    Low-dose chemotherapy remodels hepatic immune landscape and potentiates anti-tumor response to immune checkpoint blockade in cholangiocarcinoma.
    Hepatology. 2026 Mar 4. doi: 10.1097/HEP.0000000000001735.
    >> Share

    February 2026
  2. CHEN S, Wan C, Yu C, Shen T, et al
    Dietary anthocyanins alleviates age-dependent hepatic steatosis by expanding Limosilactobacillus reuteri and modulating gut microbiota-bile acid-hepatic FXR signaling.
    Hepatology. 2026 Feb 24. doi: 10.1097/HEP.0000000000001721.
    >> Share

  3. BITTERMANN T, Leonard CE
    Stains in primary biliary cholangitis: Untangling promise from bias.
    Hepatology. 2026 Feb 19. doi: 10.1097/HEP.0000000000001722.
    >> Share

  4. MARKAIDE E, Izquierdo-Sanchez L, Olaizola I, Urretabizkaia-Garmendia J, et al
    Statins halt polycystic liver disease by reprogramming metabolism and normalizing mitochondrial bioenergetics in cystic cholangiocytes.
    Hepatology. 2026 Feb 10. doi: 10.1097/HEP.0000000000001711.
    >> Share

  5. WU CW, Lui RN
    Unravelling the immunogenetic architecture of cholangiocarcinoma.
    Hepatology. 2026 Feb 6. doi: 10.1097/HEP.0000000000001712.
    >> Share

  6. LEUNG KK, Li W, Hansen B, Gulamhusein A, et al
    Understanding hepatopancreatobiliary cancer risks in a population-based primary sclerosing cholangitis-inflammatory bowel disease cohort.
    Hepatology. 2026 Feb 4. doi: 10.1097/HEP.0000000000001692.
    >> Share

  7. HAN Y, Byun J, VanLith CJ, Cooley MA, et al
    Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses.
    Hepatology. 2026 Feb 2. doi: 10.1097/HEP.0000000000001699.
    >> Share

  8. CHOI J, Xu J, Nguyen VH, Przybyszewski E, et al
    Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study.
    Hepatology. 2026 Feb 2. doi: 10.1097/HEP.0000000000001701.
    >> Share

  9. UDOMPAP P
    Metabolic syndrome and cholangiocarcinoma: A signal too strong to ignore.
    Hepatology. 2026;83:195-196.
    >> Share

    January 2026
  10. SABOROWSKI A, Peters S, Zhao J, Marhenke S, et al
    Stroma-driven inter- and intratumoral heterogeneity of PD-L1 expression in cholangiocarcinoma: Implications for biomarker development and prognostic evaluation.
    Hepatology. 2026 Jan 26. doi: 10.1097/HEP.0000000000001686.
    >> Share

  11. DONG Y, Stumpf HE, Smoot RL, Starlinger PP, et al
    Anatomic subsets of cholangiocarcinoma: More different than alike.
    Hepatology. 2026 Jan 12. doi: 10.1097/HEP.0000000000001672.
    >> Share

  12. WANG W, Yin S, Xu Q, Song D, et al
    Biologically interpretable deep learning-derived MRI phenotypes reveal lymph node involvement and neoadjuvant therapy response in intrahepatic cholangiocarcinoma.
    Hepatology. 2026 Jan 12. doi: 10.1097/HEP.0000000000001671.
    >> Share

    December 2025
  13. WOO S, Kang B, Lee SH, Kim JS, et al
    Biology-driven stratification of advanced biliary tract cancer treated with nab-paclitaxel plus gemcitabine-cisplatin: A prospective observational cohort study.
    Hepatology. 2025 Dec 19. doi: 10.1097/HEP.0000000000001650.
    >> Share

  14. XUN Z, Wang H, Xuan Z, Xiong K, et al
    Spatiotemporal landscape of intrahepatic cholangiocarcinoma liver metastasis at the single-cell level.
    Hepatology. 2025 Dec 10. doi: 10.1097/HEP.0000000000001641.
    >> Share

  15. HUSSAIN N, Motta RV, Gungabissoon U, Casillas L, et al
    Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity.
    Hepatology. 2025 Dec 5. doi: 10.1097/HEP.0000000000001634.
    >> Share

    November 2025
  16. XIE M, Wu H, Xu J
    Letter to the Editor: From risk alert to decision support: Enhancing the clinical value of the AI model for cholangiocarcinoma.
    Hepatology. 2025 Nov 11. doi: 10.1097/HEP.0000000000001610.
    >> Share

  17. SINGH Y, Eaton JE, Erickson BJ, Gores GJ, et al
    Reply: From risk alert to decision support: Enhancing the clinical value of the AI Model for cholangiocarcinoma.
    Hepatology. 2025 Nov 11. doi: 10.1097/HEP.0000000000001611.
    >> Share

    October 2025
  18. WEI T, Ma ZJ, Guo S, Weiss M, et al
    Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling.
    Hepatology. 2025 Oct 30. doi: 10.1097/HEP.0000000000001594.
    >> Share

  19. WENG D, Huang G, Liu Y
    Letter to the Editor: Clarifying the relative contributions of collagen architecture and stiffness to antitumor immunity in GIONF-Enhanced PD-1 blockade for cholangiocarcinoma.
    Hepatology. 2025 Oct 29. doi: 10.1097/HEP.0000000000001598.
    >> Share

  20. GRIMAUD E, Gardin A, Ackermann O, Habes D, et al
    Serum bile acid levels predict the development of portal hypertension and high-risk esophageal varices following successful Kasai in biliary atresia.
    Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001592.
    >> Share

  21. XU M, Ju-Seog L
    Multi-omics and machine learning in cholangiocarcinoma: A paradigm shift toward molecular subtyping and precision therapy.
    Hepatology. 2025 Oct 2. doi: 10.1097/HEP.0000000000001560.
    >> Share

  22. MININI M, Avveduto G, Becharef S, Meunier-Thaens M, et al
    Laser-activated nanoparticles rewire tumor microenvironment enhancing PD-1 blockade and T cell response in cholangiocarcinoma.
    Hepatology. 2025 Oct 2. doi: 10.1097/HEP.0000000000001545.
    >> Share

  23. HORST LJ, Kempski J, Walmsley M, Huber S, et al
    PSC and colitis: A complex relationship.
    Hepatology. 2025;82:960-984.
    >> Share

    September 2025
  24. MUN DG, Jessen E, Tomlinson JL, Carlson D, et al
    Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic target.
    Hepatology. 2025 Sep 29. doi: 10.1097/HEP.0000000000001535.
    >> Share

  25. TESINI G, Ibrahim H, Rimassa L, Braconi C, et al
    Evolving Precision: Updates in Targeted Therapy for Cholangiocarcinoma.
    Hepatology. 2025 Sep 22. doi: 10.1097/HEP.0000000000001541.
    >> Share

  26. SIMBRUNNER B, Paternostro R, Reiberger T, Trauner M, et al
    Bile acid signaling in MASLD: from pathogenesis to therapeutic applications.
    Hepatology. 2025 Sep 19. doi: 10.1097/HEP.0000000000001539.
    >> Share

  27. DONG Y, Li Z, Gores GJ, Heimbach JK, et al
    Reply: Re-examining neoadjuvant chemoradiation plus transplantation versus liver resection for de novo perihilar cholangiocarcinoma.
    Hepatology. 2025 Sep 10. doi: 10.1097/HEP.0000000000001521.
    >> Share

  28. LI Y, Fan X, Xu X
    Letter to the editor: Re-examining neoadjuvant chemoradiation plus transplantation versus liver resection for de novo perihilar cholangiocarcinoma.
    Hepatology. 2025 Sep 10. doi: 10.1097/HEP.0000000000001519.
    >> Share

  29. WILECHANSKY RM
    Surging sludge: Intrahepatic cholangiocarcinoma mortality on the rise worldwide.
    Hepatology. 2025;82:543-544.
    >> Share

    August 2025
  30. DING J, She HY, Cheng Y, Sun HY, et al
    A novel mechanism involving USP53-regulated BSEP trafficking underlies low-GGT intrahepatic cholestasis.
    Hepatology. 2025 Aug 19. doi: 10.1097/HEP.0000000000001501.
    >> Share

  31. ZENG Q, Xie D, Zhou Q, Qian B, et al
    Letter to the Editor: The treatment options for de novo perihilar cholangiocarcinoma require more details.
    Hepatology. 2025 Aug 13. doi: 10.1097/HEP.0000000000001496.
    >> Share

  32. DONG Y, Li Z, Gores GJ, Heimbach JK, et al
    Reply: The treatment options for de novo perihilar cholangiocarcinoma require more details.
    Hepatology. 2025 Aug 13. doi: 10.1097/HEP.0000000000001497.
    >> Share

  33. ZHANG D, Yang Y, Lu Z
    Letter to the Editor: Biliary tract cancer subtype heterogeneity: An overlooked key analytic dimension.
    Hepatology. 2025 Aug 12. doi: 10.1097/HEP.0000000000001490.
    >> Share

    July 2025
  34. FAN G, Han X, Shi Y
    Reply: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
    Hepatology. 2025 Jul 30. doi: 10.1097/HEP.0000000000001480.
    >> Share

  35. TAKEFUJI Y
    Letter to the editor: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
    Hepatology. 2025 Jul 29. doi: 10.1097/HEP.0000000000001479.
    >> Share

  36. APODAKA-BIGURI M, Simao AL, Gonzalez-Romero F, Mestre D, et al
    E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p.
    Hepatology. 2025 Jul 28. doi: 10.1097/HEP.0000000000001461.
    >> Share

  37. ABRUZZESE GA, Martinez-Chantar ML
    Minor players, major signals: Unveiling the systemic and gut-localized impact of microbial amidated bile acids in hepatopancreatobiliary disease.
    Hepatology. 2025 Jul 21. doi: 10.1097/HEP.0000000000001473.
    >> Share

  38. MARTINS A, Khakoo NS, Reddy A, Reynolds JM, et al
    Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis.
    Hepatology. 2025 Jul 15. doi: 10.1097/HEP.0000000000001465.
    >> Share

  39. NOMDEN M, Kuipers F, Lexmond WS, Gu T, et al
    Pretreatment serum bile acid composition and predictability of subsequent response to odevixibat in patients with bile salt export pump (BSEP) deficiency.
    Hepatology. 2025 Jul 11. doi: 10.1097/HEP.0000000000001430.
    >> Share

  40. DONG Y, Li Z, Podrascanin V, Eaton JE, et al
    Liver resection with and without vascular resection versus transplantation for de novo perihilar cholangiocarcinoma.
    Hepatology. 2025 Jul 4. doi: 10.1097/HEP.0000000000001449.
    >> Share

  41. GUO Y, Zhang Q, Li B, Dai W, et al
    Biliary YB-1/GLI2 axis facilitates ductular reaction and promotes hepatic stellate cell activation via SPP1/Integrin alphavbeta1 signaling during liver fibrogenesis.
    Hepatology. 2025 Jul 4. doi: 10.1097/HEP.0000000000001458.
    >> Share

  42. KENNEDY L, Hargrove L, Demieville J, Karstens W, et al
    Retraction: Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2-/- mice and human cholangiocarcinoma tumorigenesis.
    Hepatology. 2025 Jul 2. doi: 10.1097/HEP.0000000000001403.
    >> Share

  43. TRAUNER M, Karpen SJ, Dawson PA
    Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease.
    Hepatology. 2025 Jul 2. doi: 10.1097/HEP.0000000000001438.
    >> Share

  44. MANCINELLI R, Franchitto A, Glaser S, Meng F, et al
    Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8.
    Hepatology. 2025;82:E22.
    >> Share

  45. LI B, Ilyas SI
    The dynamic duo: How tumor-associated macrophages and tumor cells team up in cholangiocarcinoma.
    Hepatology. 2025;82:1-2.
    >> Share

  46. HAMMONS J, Warren EK, Wittling MC, Bennett FJ, et al
    Tumor site influences efficacy of MEKi and immunotherapy combinations in pre-clinical model of cholangiocarcinoma.
    Hepatology. 2025 Jul 1. doi: 10.1097/HEP.0000000000001439.
    >> Share

    June 2025
  47. CHUNG BK, Jordens MS, Ogaard J, Reims HM, et al
    Multimodal transcriptomics identifies metallothionein as a novel pathway in primary sclerosing cholangitis.
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001432.
    >> Share

  48. TEMPRANO AG, Romero MR, Ghallab A, Llera L, et al
    Gut-to-Bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders.
    Hepatology. 2025 Jun 23. doi: 10.1097/HEP.0000000000001441.
    >> Share

  49. CARPINO G, Overi D, Macias RI, Cardinale V, et al
    Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancement.
    Hepatology. 2025 Jun 16. doi: 10.1097/HEP.0000000000001425.
    >> Share

  50. LI F, Li Y, Wang L, Xu L, et al
    Tumor microenvironment heterogeneity and progression mechanisms in intrahepatic cholangiocarcinoma: A study based on single-cell and spatial transcriptomic sequencing.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001423.
    >> Share

  51. BIAN Q, Wang S, Song Z, Liu F, et al
    Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001422.
    >> Share

  52. YAN B, Lai W, Wang Z
    Letter to the editor: Mitigating missing data bias and confounding on large-scale cohort studies of metabolic syndrome-cholangiocarcinoma associations.
    Hepatology. 2025 Jun 3. doi: 10.1097/HEP.0000000000001418.
    >> Share

    May 2025
  53. O'ROURKE CJ, Andersen JB
    Intrahepatic Cholangiocarcinoma PANoptosidy.
    Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001398.
    >> Share

    April 2025
  54. LEE MH
    Reply: Oversights in Stratification and Viral Screening- A Critical Appraisal of a MetS-Cholangiocarcinoma Cohort.
    Hepatology. 2025 Apr 29. doi: 10.1097/HEP.0000000000001370.
    >> Share

  55. HUANG J
    Letter to the editor: Oversights in stratification and viral screening- A critical appraisal of a MetS-cholangiocarcinoma cohort.
    Hepatology. 2025 Apr 29. doi: 10.1097/HEP.0000000000001369.
    >> Share

  56. HOLMER M, Ingre M, Farkkila M, Ponsioen C, et al
    Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study.
    Hepatology. 2025 Apr 16. doi: 10.1097/HEP.0000000000001351.
    >> Share

  57. YU Y, You Y, Duan Y, Kang M, et al
    Multiomics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma.
    Hepatology. 2025 Apr 15. doi: 10.1097/HEP.0000000000001352.
    >> Share

  58. LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al
    Reply: Primary sclerosing cholangitis and autoimmune hepatitis - distinct or common autoimmune penetrance?
    Hepatology. 2025 Apr 11. doi: 10.1097/HEP.0000000000001326.
    >> Share

  59. YANG LX, Gao Q, Shi JY, Wang ZC, et al
    Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
    Hepatology. 2025 Apr 7. doi: 10.1097/HEP.0000000000001274.
    >> Share

  60. SAMPLE JW
    A Niche Discovery: Spatial Mapping of Therapeutic Targets in Biliary Atresia.
    Hepatology. 2025;81:1109-1110.
    >> Share

  61. MOL B, Werner E, Culver EL, van der Meer AJ, et al
    Epidemiological and economical burden of cholestatic liver disease.
    Hepatology. 2025 Apr 1. doi: 10.1097/HEP.0000000000001341.
    >> Share

    March 2025
  62. GRONBAEK L, Vilstrup H, Jepsen P
    Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis - distinct or common autoimmune penetrance?
    Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001325.
    >> Share

  63. LEVY C, Bowlus CL
    Erratum: Primary biliary cholangitis: Personalizing second-line therapies.
    Hepatology. 2025 Mar 24. doi: 10.1097/HEP.0000000000001275.
    >> Share

  64. MACIAS RIR, Roessler S, Verstegen MMA
    Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma.
    Hepatology. 2025 Mar 24. doi: 10.1097/HEP.0000000000001322.
    >> Share

  65. CHEN TI, Chen MH, Yin SC, Lin CJ, et al
    Associations between metabolic syndrome and cholangiocarcinoma risk: A large-scale population-based cohort study.
    Hepatology. 2025 Mar 21. doi: 10.1097/HEP.0000000000001312.
    >> Share

  66. SINGH Y, Eaton JE, Venkatesh SK, Welle CL, et al
    Deep learning analysis of magnetic resonance imaging accurately detects early-stage perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Hepatology. 2025 Mar 20. doi: 10.1097/HEP.0000000000001314.
    >> Share

  67. GORES GJ, Malhi H
    The dynamic landscape of cholestatic liver disease.
    Hepatology. 2025 Mar 7. doi: 10.1097/HEP.0000000000001298.
    >> Share

    February 2025
  68. HONG L, Mei J, Sun X, Wu Y, et al
    Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma.
    Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001283.
    >> Share

  69. CANCADO GGL, Deeb M, Gulamhusein AF
    Liver transplantation for cholestatic liver diseases: Timing & disease recurrence.
    Hepatology. 2025 Feb 17. doi: 10.1097/HEP.0000000000001268.
    >> Share

  70. OLAIZOLA P, Olaizola I, Fernandez de Ara M, Lapitz A, et al
    Targeting protein hyperSUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma crosstalk.
    Hepatology. 2025 Feb 11. doi: 10.1097/HEP.0000000000001259.
    >> Share

  71. YU M, Sample JW, Yan IK, Takaichi S, et al
    Aptamer-directed, nanovesicle-mediated targeting of undruggable molecules in preclinical cholangiocarcinoma models.
    Hepatology. 2025 Feb 10. doi: 10.1097/HEP.0000000000001256.
    >> Share

  72. LI B
    BileMet: A new frontier in distinguishing malignant from benign biliary conditions.
    Hepatology. 2025;81:383-384.
    >> Share

    January 2025
  73. LI B, Ilyas SI
    Unveiling the immune landscape of IDH1-mutant cholangiocarcinoma: Pathways to new therapies.
    Hepatology. 2025 Jan 21. doi: 10.1097/HEP.0000000000001241.
    >> Share

  74. RONCA V, Davies SP, Oo YH, Lleo A, et al
    The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects.
    Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001225.
    >> Share

  75. IDALSOAGA F, Arab JP
    Unraveling bile acid dynamics in severe obesity.
    Hepatology. 2025;81:1-2.
    >> Share

    December 2024
  76. BITTERMANN T, Schaubel DE
    Obeticholic acid as second-line therapy for primary biliary cholangitis: Does target trial emulation solve the issue?
    Hepatology. 2024 Dec 20. doi: 10.1097/HEP.0000000000001198.
    >> Share

  77. THI VU Q, Nishimura Y, Harada K, Ito H, et al
    International trends in biliary tract cancer-related mortality, 2000-2022: An observational study of the World Health Organization mortality database.
    Hepatology. 2024 Dec 19. doi: 10.1097/HEP.0000000000001200.
    >> Share

  78. LUO Y, Fraser L, Jezykowski J, Gupta NA, et al
    Interleukin 8-CXCR2 mediated neutrophil extracellular trap (NET) formation in biliary atresia associated with NET-Induced stellate cell activation.
    Hepatology. 2024 Dec 18. doi: 10.1097/HEP.0000000000001195.
    >> Share

  79. CONDE DE LA ROSA L, Fabrega L, Torres S, Nunez S, et al
    Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity.
    Hepatology. 2024 Dec 9. doi: 10.1097/HEP.0000000000001184.
    >> Share

  80. ZABRANSKY DJ, Kartalia E, Lee JW, Leatherman JM, et al
    Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma.
    Hepatology. 2024 Dec 3. doi: 10.1097/HEP.0000000000001185.
    >> Share

  81. BROOKHART MA, Mayne TJ, Coombs C, Breskin A, et al
    Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.
    Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001174.
    >> Share

    November 2024
  82. KARLSEN TH, Kaasen Jorgensen K, Bergquist A
    Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
    Hepatology. 2024 Nov 22. doi: 10.1097/HEP.0000000000001172.
    >> Share

  83. LEVY C, Bowlus CL
    Primary Biliary Cholangitis: personalizing second-line therapies.
    Hepatology. 2024 Nov 12. doi: 10.1097/HEP.0000000000001166.
    >> Share

    October 2024
  84. FAN G, Tao C, Li L, Xie T, et al
    The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells determined the poor prognosis in intrahepatic cholangiocarcinoma.
    Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001138.
    >> Share

  85. CIRIA R, Ivanics T, Aliseda D, Claasen M, et al
    Liver transplantation for primary and secondary liver tumours. patient-level meta-analyses compared to unos conventional indications.
    Hepatology. 2024 Oct 28. doi: 10.1097/HEP.0000000000001129.
    >> Share

  86. SCHNEIDER KM, Kummen M, Trivedi PJ, Hov JR, et al
    Role of microbiome in autoimmune liver diseases.
    Hepatology. 2024;80:965-987.
    >> Share

    September 2024
  87. JALAN-SAKRIKAR N, Guicciardi ME, O'Hara SP, Azad A, et al
    Central role for cholangiocyte pathobiology in cholestatic liver diseases.
    Hepatology. 2024 Sep 9. doi: 10.1097/HEP.0000000000001093.
    >> Share

  88. CORNILLET M, Geanon D, Bergquist A, Bjorkstrom NK, et al
    Immunobiology of primary sclerosing cholangitis.
    Hepatology. 2024 Sep 2. doi: 10.1097/HEP.0000000000001080.
    >> Share

    August 2024
  89. PANT K, Richard S, Peixoto E, Baral S, et al
    Cholangiocyte ciliary defects induce sustained epidermal growth factor receptor signaling.
    Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001055.
    >> Share

  90. XIAO MH, Ma D, Wu S, Huang Z, et al
    Integrative single-cell and spatial transcriptomic analyses identify a pathogenic cholangiocyte niche and TNFRSF12A as therapeutic target for biliary atresia.
    Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001064.
    >> Share

  91. BJORNSSON ES, Devarbhavi HC
    Drug induced cholestatic liver diseases.
    Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001052.
    >> Share

  92. BANALES JM, Lapitz A, Fabris L
    Comparative performance of methylation DNA markers, brushing cytology, and FISH in diagnosing malignant biliary strictures.
    Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001050.
    >> Share

    July 2024
  93. ZHANG X, Liu H, Cai P, Huang Z, et al
    Mdka produced by the activated HSCs drives bipotential progenitor cell redifferentiation during zebrafish biliary-mediated liver regeneration.
    Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001031.
    >> Share

  94. SUTTON H, Sokol RJ, Kamath BM
    IBAT inhibitors in pediatric cholestatic liver diseases: Transformation on the horizon?
    Hepatology. 2024 Jul 25. doi: 10.1097/HEP.0000000000001032.
    >> Share

  95. ZHUANG Y, Ortega-Ribera M, Szabo G
    Reply to: Exercise greater caution in bile acid research.
    Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001017.
    >> Share

  96. YI C, Chen L, Tao B, Wang X, et al
    Letter to the Editor: Exercise greater caution in bile acid research.
    Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001013.
    >> Share

  97. ZHANG L, Xie P, Li M, Zhang X, et al
    Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation.
    Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000001003.
    >> Share

    June 2024
  98. ZHU M, Qu M, Lv S, Pan F, et al
    Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study.
    Hepatology. 2024 Jun 24. doi: 10.1097/HEP.0000000000000932.
    >> Share

  99. COOLEY MA, Schneider AR, Barr Fritcher EG, Milosevic D, et al
    Utility of methylated DNA markers for the diagnosis of malignant biliary strictures.
    Hepatology. 2024 Jun 21. doi: 10.1097/HEP.0000000000000970.
    >> Share

  100. OH DY, Ikeda M, Lee CK, Rojas C, et al
    Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial.
    Hepatology. 2024 Jun 14. doi: 10.1097/HEP.0000000000000965.
    >> Share

  101. YANG S, Fu J, Qin W, Wang R, et al
    Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases.
    Hepatology. 2024 Jun 11. doi: 10.1097/HEP.0000000000000957.
    >> Share

  102. HUANG YH, Loftfield E, Argirion I, Adami HO, et al
    Association of tea and coffee consumption and biliary tract cancer risk: The Biliary Tract Cancers Pooling Project.
    Hepatology. 2024;79:1324-1336.
    >> Share

  103. HANSEN BE, Vandriel SM, Vig P, Garner W, et al
    Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
    Hepatology. 2024;79:1279-1292.
    >> Share

    May 2024
  104. AYDIN O, Wahlstrom A, de Jonge PA, Meijnikman AS, et al
    An integrated analysis of bile acid metabolism in humans with severe obesity.
    Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000938.
    >> Share

  105. KELLERMAYER R, Carbone M, Horvath TD, Szigeti RG, et al
    Identifying a therapeutic window of opportunity for people living with primary sclerosing cholangitis: Embryology and the overlap of inflammatory bowel disease with immune mediated liver injury.
    Hepatology. 2024 May 14. doi: 10.1097/HEP.0000000000000926.
    >> Share

    April 2024
  106. HITOMI Y, Ueno K, Aiba Y, Nishida N, et al
    A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis.
    Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000894.
    >> Share

    March 2024
  107. JONES DE, Beuers U, Bonder A, Carbone M, et al
    Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
    Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000864.
    >> Share

  108. LAL BB, Alam S, Sibal A, Kumar K, et al
    Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency-related cholestasis.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000828.
    >> Share

  109. AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
    Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
    >> Share

  110. PANDURANGI S, Mourya R, Nalluri S, Fei L, et al
    Diagnostic accuracy of serum matrix metalloproteinase-7 as a biomarker of biliary atresia in a large North American cohort.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000827.
    >> Share

  111. ZHUANG Y, Szabo G
    Reply to: How does bile acid-induced IRF3 phosphorylation mediate cholestatic liver and kidney injury? more need to be known.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000816.
    >> Share

  112. KELLERER M, Javed S, Casar C, Will N, et al
    Antagonistic effects of the cytotoxic molecules granzyme B and TRAIL in the immunopathogenesis of sclerosing cholangitis.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000830.
    >> Share

  113. JIANG L, Yang Z
    Letter to the Editor: How does bile acid-induced IRF3 phosphorylation mediate cholestatic liver and kidney injury? ---more need to be known.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000813.
    >> Share

  114. LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al
    Autoimmune diseases in primary sclerosing cholangitis and their first-degree relatives.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000823.
    >> Share

    February 2024
  115. ZHANG H, Zhu K, Zhang R, Guo Y, et al
    Oleic acid-PPARgamma-FABP4 loop fuels cholangiocarcinoma colonization in lymph node metastases microenvironment.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000784.
    >> Share

    January 2024
  116. WILBUR HC, Soares HP, Azad NS
    Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations.
    Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000760.
    >> Share

  117. BARGELLINI I, Rimassa L, Masi G
    SIRT and chemotherapy in unresectable iCCA: Ready to take off.
    Hepatology. 2024;79:9-11.
    >> Share

  118. CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
    Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
    Hepatology. 2024;79:39-48.
    >> Share

    December 2023
  119. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
    Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
    >> Share

  120. WIEGAND J, Franke A, Stein K, Trautwein C, et al
    Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
    >> Share

  121. KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al
    Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
    Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728.
    >> Share

    November 2023
  122. GHOSH S, Devereaux MW, Liu C, Sokol RJ, et al
    LRH-1 agonist DLPC through STAT6 promotes macrophage polarization and prevents parenteral nutrition associated cholestasis in mice.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000690.
    >> Share

  123. GEHL V, O'Rourke CJ, Andersen JB
    Immunogenomics of cholangiocarcinoma.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000688.
    >> Share

  124. HE S, Peng Y, Wei Q
    Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000685.
    >> Share

  125. SLOOTER CD, van den Brand FF, Lleo A, Liberal R, et al
    Reply - Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000689.
    >> Share

  126. LIU ZP, Sun XH, Yu C, Yin XY, et al
    Letter to the Editor: How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma?
    Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000651.
    >> Share

  127. NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
    ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
    Hepatology. 2023;78:1337-1351.
    >> Share

  128. YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
    Metabolic reprogramming and its clinical implication for liver cancer.
    Hepatology. 2023;78:1602-1624.
    >> Share

    October 2023
  129. RATTI F, Marino R, Groot Koerkamp B, Aldrighetti L, et al
    Reply: "How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma".
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000659.
    >> Share

  130. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
    Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
    Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
    >> Share

  131. HU YF, Ma WJ, Jin YW, Li FY, et al
    Adjuvant chemotherapy for resected biliary tract cancers: A fluorouracil-based scheme beats out a gemcitabine-based scheme for the win.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000634.
    >> Share


  132. Erratum: Modulation of the tryptophan hydroxylase 1/monoamine oxidase-A/5-hydroxytryptamine/5-hydroxytryptamine receptor 2A/2B/2C axis regulates biliary proliferation and liver fibrosis during cholestasis.
    Hepatology. 2023;78:E86.
    >> Share

    September 2023
  133. GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
    Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
    >> Share

  134. ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
    Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
    >> Share

  135. SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al
    Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589.
    >> Share

    August 2023
  136. PEISELER M, Tacke F
    Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
    Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.
    >> Share

  137. RATTI F, Marino R, Olthof PB, Pratschke J, et al
    Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine learning analytics model to optimize treatment allocation.
    Hepatology. 2023 Aug 3. doi: 10.1097/HEP.0000000000000554.
    >> Share

  138. DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
    Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
    >> Share

  139. BOWLUS CL, Levy C
    Optimizing treatment of primary biliary cholangitis: Is good, good enough?
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
    >> Share

    July 2023
  140. ZHAO L, Liu J, Li K, Zhang C, et al
    PTPN9 dephosphorylates FGFR2pY656/657 via interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.
    Hepatology. 2023 Jul 27. doi: 10.1097/HEP.0000000000000552.
    >> Share

  141. LI Y, Li B, Xiao X, Qian Q, et al
    Itaconate inhibits CD103+ TRM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.
    Hepatology. 2023 Jul 26. doi: 10.1097/HEP.0000000000000549.
    >> Share

  142. EDELINE J, Bridgewater J, Campillo-Gimenez B, Neveu E, et al
    Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials.
    Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000544.
    >> Share


  143. Retraction: Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000484.
    >> Share

  144. JEONG H, Yoo C
    Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial - author's reply.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000535.
    >> Share

  145. HU YF, Gu HF, Jin YW, Li FY, et al
    Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000532.
    >> Share

    June 2023
  146. SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
    Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
    Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
    >> Share

  147. EKSER B, Sucu S, Mihaylov P, Emamaullee JA, et al
    Letter to the Editor mucosal gut microbiota in primary sclerosing cholangitis before and after liver transplantation: Are there other challenges?
    Hepatology. 2023 Jun 5. doi: 10.1097/HEP.0000000000000503.
    >> Share

    May 2023
  148. NEJAK-BOWEN K, Monga SP
    Wnt-beta-catenin in hepatobiliary homeostasis, injury, and repair.
    Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000495.
    >> Share


  149. Erratum: IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2023 May 15. doi: 10.1097/HEP.0000000000000040.
    >> Share

  150. SHU L, Li X, Liu Z, Li K, et al
    Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation.
    Hepatology. 2023 May 5. doi: 10.1097/HEP.0000000000000437.
    >> Share

  151. JEONG H, Kim KP, Jeong JH, Hwang DW, et al
    Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
    Hepatology. 2023;77:1540-1549.
    >> Share

  152. FORMAN LM, Sapisochin G, Assis DN, Arrive L, et al
    Reply: Living donor liver transplantation for people with PSC.
    Hepatology. 2023;77:E97-E98.
    >> Share

    April 2023
  153. MACKOWIAK B, Gao B
    Activation of cholangiocyte mTORC1 drives alcohol-induced ductular reaction.
    Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000416.
    >> Share

  154. RUSSI AE, Shivakumar P, Luo Z, Bezerra J, et al
    Plasticity between ILC2 subsets and amphiregulin expression regulate epithelial repair in biliary atresia.
    Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000418.
    >> Share

  155. DANIEL N, Genua F, Jenab M, Mayen AL, et al
    The role of the gut microbiome in the development of hepatobiliary cancers.
    Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000406.
    >> Share

  156. HARTL L, Reiberger T, Trauner M
    Reply: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000399.
    >> Share

  157. UMAR S, Nadeem A, Nadeem M
    Letter to the editor: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000398.
    >> Share

  158. HIRSCHFIELD GM, Shiffman ML, Gulamhusein A, Kowdley KV, et al
    Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
    Hepatology. 2023 Apr 6. doi: 10.1097/HEP.0000000000000395.
    >> Share

  159. YOO C, Javle MM, Verdaguer Mata H, de Braud F, et al
    Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000365.
    >> Share

  160. CABALLERO-CAMINO FJ, Rodrigues PM, Wangsell F, Agirre-Lizaso A, et al
    A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multi-organ activity and shows translational relevance to humans.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000376.
    >> Share

  161. SINGH SP, Mondia N
    Letter to the Editor: Much more needed in natural history of Alagille syndrome.
    Hepatology. 2023;77:E78.
    >> Share

    January 2023
  162. CANTALLOPS VILA P, Ravichandra A, Agirre Lizaso A, Perugorria MJ, et al
    Heterogeneity, crosstalk and targeting of cancer associated fibroblasts in cholangiocarcinoma.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000206.
    >> Share

  163. HEINEMANN M, Adam R, Karam V, Schramm C, et al
    Letter to the Editor: Living donor liver transplantation for people with PSC.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000208.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016